Innoviva, Inc. engages in the development and commercialization of pharmaceuticals.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$15.91|
|52 Week High||US$9.21|
|52 Week Low||US$17.45|
|1 Month Change||-1.67%|
|3 Month Change||16.64%|
|1 Year Change||65.21%|
|3 Year Change||6.78%|
|5 Year Change||56.44%|
|Change since IPO||-12.15%|
Recent News & Updates
Is Innoviva (NASDAQ:INVA) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Taking Profits In Innoviva Inc.
Results so far in 2021 have been impressive, with both revenue and net income much higher than the same periods in either 2020 or 2019. That said, the company fired a massive buyback program in the 2nd quarter and it seems the market yawned. This makes me wonder what will happen absent buybacks. I suggested investors also sell puts here. I take this opportunity to drone on yet again about the risk reducing, return-enhancing power of these options.
Innoviva reports Q1 results
Innoviva (INVA): Q1 GAAP EPS of $0.84.Revenue of $85.52M (+8.7% Y/Y)Shares +1.8% AH.Press Release
|INVA||US Pharmaceuticals||US Market|
Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 16.8% over the past year.
Return vs Market: INVA exceeded the US Market which returned 33.4% over the past year.
Stable Share Price: INVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: INVA's weekly volatility (5%) has been stable over the past year.
About the Company
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
Innoviva Fundamentals Summary
|INVA fundamental statistics|
Is INVA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INVA income statement (TTM)|
|Cost of Revenue||US$1.32m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||3.82|
|Net Profit Margin||72.56%|
How did INVA perform over the long term?See historical performance and comparison
Is Innoviva undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INVA ($15.91) is trading below our estimate of fair value ($161.77)
Significantly Below Fair Value: INVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INVA is good value based on its PE Ratio (4.2x) compared to the US Pharmaceuticals industry average (20.6x).
PE vs Market: INVA is good value based on its PE Ratio (4.2x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INVA is overvalued based on its PB Ratio (3.4x) compared to the US Pharmaceuticals industry average (3.1x).
How is Innoviva forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if INVA's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if INVA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INVA's revenue is expected to decline over the next 3 years (-20.7% per year).
High Growth Revenue: INVA's revenue is forecast to decline over the next 3 years (-20.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INVA's Return on Equity is forecast to be low in 3 years time (16.2%).
How has Innoviva performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INVA has a large one-off gain of $80.3M impacting its June 30 2021 financial results.
Growing Profit Margin: INVA's current net profit margins (72.6%) are lower than last year (76.2%).
Past Earnings Growth Analysis
Earnings Trend: INVA's earnings have grown significantly by 25% per year over the past 5 years.
Accelerating Growth: INVA's earnings growth over the past year (16.3%) is below its 5-year average (25% per year).
Earnings vs Industry: INVA earnings growth over the past year (16.3%) underperformed the Pharmaceuticals industry 17.5%.
Return on Equity
High ROE: INVA's Return on Equity (85.6%) is considered outstanding.
How is Innoviva's financial position?
Financial Position Analysis
Short Term Liabilities: INVA's short term assets ($148.3M) exceed its short term liabilities ($5.4M).
Long Term Liabilities: INVA's short term assets ($148.3M) do not cover its long term liabilities ($390.0M).
Debt to Equity History and Analysis
Debt Level: INVA's debt to equity ratio (99%) is considered high.
Reducing Debt: INVA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: INVA's debt is well covered by operating cash flow (84.2%).
Interest Coverage: INVA's interest payments on its debt are well covered by EBIT (18.7x coverage).
What is Innoviva current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: INVA is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Pavel Raifeld (37 yo)
Mr. Pavel Raifeld, CFA, serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive with a strong background in strategy, business development and corporate fi...
CEO Compensation Analysis
Compensation vs Market: Pavel's total compensation ($USD1.94M) is about average for companies of similar size in the US market ($USD2.25M).
Compensation vs Earnings: Insufficient data to compare Pavel's compensation with company performance.
Experienced Board: INVA's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: INVA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Innoviva, Inc.'s employee growth, exchange listings and data sources
- Name: Innoviva, Inc.
- Ticker: INVA
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.106b
- Shares outstanding: 69.49m
- Website: https://www.inva.com
Number of Employees
- Innoviva, Inc.
- 1350 Old Bayshore Highway
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:30|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.